Is Etrasimod-Velsipity currently available in China?

As ofSeptember 2025,Etrasimod (Etrasimod) has not been officially launched in China, nor has it been included in the national medical insurance reimbursement catalog. Although domestic patients still cannot obtain the drug directly through hospital pharmacies, its overseas marketing experience and clinical data have important reference value for domestic treatment strategies. Itrimod is a selective S1P receptor modulator that reduces intestinal inflammation by regulating lymphocyte migration, thereby improving symptoms and mucosal inflammation in patients with ulcerative colitis(UC).

Overseas, itrimod has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of moderately to severely active ulcerative colitis. The drug is taken orally once daily and is easy to use, which has significant advantages for patients who require long-term maintenance treatment. Foreign original drugs provide a stable supply chain and complete clinical data support, showing good efficacy and tolerability. These data provide an important basis for domestic doctors' future clinical application after the drug is approved, and also provide a reliable treatment reference for patients and families.

Domestically, a new drug application (NDA) for itridimod has been officially submitted to the China National Medical Products Administration for the treatment of patients with moderately to severely active ulcerative colitis. The drug approval process includes drug quality evaluation, clinical data review and safety assessment. It is expected that in the next few years, if approved, itrimod will become the first oral S1P receptor modulator in China, adding new options for the treatment of ulcerative colitis.

If it is not yet on the market, domestic patients who want to learn more about this drug can refer to overseas clinical experience, such as the maintenance period of the efficacy, its effect on intestinal mucosal healing, and potential strategies for combined use with traditional immunosuppressants or biological agents. At the same time, attention should be paid to the medical insurance policies and prices of drugs after they are launched in China, so as to plan treatment plans rationally.

Reference materials:https://www.drugs.com/mtm/etrasimod.html